Once-daily administration of phosphodiesterase type 5 inhibitors has been shown to correct erectile dysfunction (ED).
To evaluate the long-term efficacy and safety after once-daily oral administration of udenafil 75 mg in men with ED.
Udenafil, a cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) inhibitor, has been developed to treat erectile dysfunction. We evaluated the effect of age on the pharmacokinetics and tolerability of udenafil.
Login to update email address, newsletter preferences and use bookmarks.